Guardant Health (GH) Azione Prezzo
Guardant Health Prezzo
Negli ultimi 9 anni Guardant Health ha aumentato il fatturato del 52,3% all'anno, raggiungendo 978,12 Mio. USD. Per Guardant Health, il margine netto del -42,6% risulta in aumento rispetto al -109,3% di alcuni anni fa. Il target di prezzo di consenso a 12 mesi per Guardant Health è 195,00 USD, circa il 22,9% sopra il prezzo attuale di mercato. Su 35 analisti, 32 valutano il titolo come acquisto — nel complesso un consenso Acquistare.
Guardant Health Prezzo delle azioni
Accedi a questi dati tramite l’API Eulerpool
100.000 richieste/mese gratis · nessuna carta di credito
Guardant Health Azione e analisi azionaria
Domande frequenti sull'azione Guardant Health
The main competitors of Guardant Health Inc in the market include companies such as Foundation Medicine, Exact Sciences Corporation, and Illumina Inc.
The business model of Guardant Health Inc. revolves around precision oncology and liquid biopsy. As a leading precision oncology company, Guardant Health develops and commercializes blood tests that can detect and monitor cancer. By analyzing the genetic alterations in circulating tumor DNA, Guardant Health enables oncologists to make more informed treatment decisions for their patients. The company's comprehensive liquid biopsy platform, including their flagship product Guardant360, provides a non-invasive alternative to traditional tissue biopsies. With their commitment to advancing cancer care, Guardant Health Inc. aims to improve patient outcomes through their innovative molecular diagnostics and therapeutic development solutions.
Guardant Health Inc is primarily active in the healthcare industry.
Guardant Health Inc. is a leading precision oncology company specializing in blood-based cancer tests. Founded in 2012, Guardant Health has rapidly grown to become a prominent player in the field of liquid biopsy. The company's breakthrough technology, Guardant360, enables comprehensive genomic profiling of solid tumors through a simple blood draw, facilitating personalized treatment decisions for cancer patients. With an extensive database of over 120,000 patients, Guardant Health Inc. is revolutionizing cancer diagnostics and therapy selection. Guardant Health is committed to advancing precision oncology and improving patient outcomes through its innovative genomic testing solutions.
Some significant milestones achieved by Guardant Health Inc include the successful completion of their initial public offering (IPO) in October 2018, generating over $235 million in funding. Additionally, the company's liquid biopsy test, Guardant360, received breakthrough device designation from the U.S. FDA in 2018, highlighting its potential impact in cancer diagnostics. Guardant Health Inc also expanded its global presence by establishing partnerships with several pharmaceutical companies and collaborating with research institutions. These achievements demonstrate Guardant Health Inc's growth as a leader in precision oncology, offering innovative solutions and advancing cancer care.
Guardant Health Inc is primarily present in the United States.
Guardant Health Inc represents values of innovation, precision, and compassion in the field of comprehensive cancer care. As a leading precision oncology company, Guardant Health is committed to transforming cancer treatment through advanced diagnostics and therapeutics. With their liquid biopsy technology, they aim to provide personalized and non-invasive genomic profiling, aiding in early cancer detection and treatment decisions. Guardant Health's corporate philosophy revolves around collaboration and empowerment, as they strive to improve patient outcomes and ease the burden of cancer. By combining cutting-edge technology with compassionate care, Guardant Health Inc epitomizes a commitment to revolutionizing cancer care for a better future.
Gli analisti fissano attualmente un prezzo obiettivo medio di 188,80 USD per l’azione Guardant Health (mediana: 195,00 USD), pari a +19,0 % rispetto all’ultimo prezzo. Il consenso si basa su 35 giudizi di analisti.
35 analisti valutano attualmente l’azione Guardant Health: 32 raccomandano l’acquisto, 3 la tenuta e 0 la vendita. Per il 2026 gli analisti si aspettano per Guardant Health ricavi pari a 1,36 miliardi USD e un utile per azione di -3,26 USD.
Convertita al tasso di cambio attuale, l’azione Guardant Health quota 141,12 EUR (158,65 USD).
L’azione Guardant Health (GH) è quotata su 5 borse, tra cui: NASDAQ (GH), XETRA (5GH.DE), Frankfurt (5GH.F), München (5GH.MU), Düsseldorf (5GH.DU).
Guardant Health Inc. is a leading company in the field of liquid biopsy and cancer early detection. The company offers innovative solutions and technologies for cancer prevention, diagnosis, and therapy. Guardant Health has two different business units: Guardant360 and GuardantOMNI. Both divisions differ in their target audience and product portfolio. Guardant360 is a blood test that captures the DNA profile of tumor cells, thereby identifying the genetic fingerprint of cancer cells. This allows for more precise and faster diagnosis. The technology of Guardant360 is used by doctors and oncologists to analyze the genetic profiles of tumor cells in real-time and develop the best possible therapy for the patient. GuardantOMNI is a comprehensive cancer genomic test that covers over 500 genes, enabling an accurate diagnosis. GuardantOMNI is used by pharmaceutical companies to develop personalized therapies and drugs. Guardant Health is committed to advancing precision medicine in the field of cancer diagnostics and therapy. By using liquid biopsy technologies, doctors and oncologists can make accurate diagnoses and offer targeted therapy. Guardant Health has also partnered with renowned pharmaceutical companies such as Merck, Bristol-Myers Squibb, and Amgen to develop personalized therapies. In addition, the company has conducted its own clinical study on cancer early detection, and further studies are planned. The business model of Guardant Health is based on selling its products and solutions to medical facilities such as hospitals, laboratories, and oncologists. The company also generates revenue through partnerships with pharmaceutical companies and participation in clinical trials. Overall, Guardant Health is a company with a promising business model based on the use of liquid biopsy technologies. The company aims to revolutionize cancer diagnostics and therapy and offer personalized medicine. The wide portfolio of solutions and products from Guardant Health allows it to cater to the needs of doctors, oncologists, and pharmaceutical companies.
Il attesa fatturato di Guardant Health ammonta a 1,36 miliardi USD. Questo dato si basa sui dati finanziari attuali e riflette lo sviluppo commerciale dell'azienda.
Il attesa profitto di Guardant Health ammonta a -419,42 Mio. USD. L'utile netto riflette la redditività dell'azienda dopo la deduzione di tutti i costi.
Il rapporto prezzo/utili (P/E) di Guardant Health è attualmente -48,67. Il rapporto P/E confronta il prezzo attuale dell'azione con l'utile per azione e aiuta gli investitori a valutare la valutazione dell'azione Guardant Health.
Il rapporto prezzo/fatturato (P/S) di Guardant Health è attualmente 15,03. Il rapporto P/S confronta la capitalizzazione di mercato con il fatturato annuo e funge da indicatore di valutazione dell'azione Guardant Health.
Il Quality Score AlleAktien per Guardant Health è 3/10.
L'ISIN di Guardant Health è US40131M1099. L'ISIN (International Securities Identification Number) è un codice identificativo univoco a livello mondiale per i titoli.
Il WKN di Guardant Health è A2N5RY. Il WKN (Wertpapierkennnummer) è un codice identificativo tedesco a sei cifre per i titoli.
Il ticker di Guardant Health è GH. Con questo simbolo di borsa vengono negoziate le azioni Guardant Health in borsa.
Azione Guardant Health
Gruppo di pari di Guardant Health
Guardant Health Ticker
Guardant Health FIGI
Altre metriche e analisi di Guardant Health in Deep Dive.
La nostra analisi azionaria dell'azione Guardant Health include importanti indicatori finanziari come il fatturato, l'utile, il P/E, il P/S, l'EBIT, oltre a informazioni sul dividendo. Inoltre, esaminiamo aspetti come le azioni, la capitalizzazione di mercato, il debito, il patrimonio netto e le passività di Guardant Health. Se state cercando informazioni più dettagliate su questi temi, sulle nostre sottopagine offriamo analisi approfondite: